Sign In
Buy SAN
$12.47
+0.310 (+2.55%)
At Close: Jun 04, 2026
Santander UK 'weaker' first-quarter numbers send rival bank shares lower
08:06am, Tuesday, 25'th Apr 2023
UK banks NatWest, Lloyds and Barclays fell ahead of the release of quarterly results later this week and next as numbers from rival Santander UK were weaker than expected, with higher costs, credit im
Santander Brasil posts Q1 net profit down 46.6%
06:52am, Tuesday, 25'th Apr 2023
Banco Santander Brasil SA on Tuesday reported a first quarter net profit of 2.14 billion reais ($425.09 million), down 46.6% from a year earlier but still above analysts' forecasts of 1.83 billion in
Banco Santander on Track to Meet 2023 Targets, CFO Says
03:02am, Tuesday, 25'th Apr 2023
Banco Santander SA Chief Financial Officer Jose Garcia Cantera discusses the Spanish lender's financial results and outlook. Santander's earnings beat estimates as tailwinds from central bank rate hik
Santander's $2.84 billion profit beats forecast, says full-year targets on track
02:08am, Tuesday, 25'th Apr 2023
Banco Santander SA on Tuesday reported an increase in net profit for the first quarter and said it is on track to meet its full-year targets.
Spain's Santander Q1 net profit rises 1% vs same period a year ago
01:00am, Tuesday, 25'th Apr 2023
Spain's Santander on Tuesday said its net profit in the first quarter rose 1% compared to the same period of 2022 as higher lending income, which offset higher provisions and the impact from a banking
BBVA, Santander, BofA want to back Mexico's $6 bln power deal - Bloomberg News
06:04pm, Thursday, 13'th Apr 2023
Banco Bilbao Vizcaya Argentaria , Banco Santander SA and Bank of America Corp together plan to fund Mexico's $6 billion deal to purchase power plants from Spain's Iberdrola , Bloomberg News reported o
Buffett is buying in Japan. This overseas value-stock fund is also making bets there. Is it a good way to diversify?
02:20pm, Thursday, 13'th Apr 2023 MarketWatch
The Columbia Overseas Value Fund is an example of an active management style of running a portfolio that doesn't mirror a stock index.
Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements
06:00am, Tuesday, 11'th Apr 2023 GlobeNewswire Inc.
Communiqué de presse : Nirsevimab : Sanofi, AstraZeneca et Sobi simplifient leurs accords contractuels
06:00am, Tuesday, 11'th Apr 2023 GlobeNewswire Inc.Santander to raise stake in Mexican unit to 99.8%, delist shares
05:23am, Tuesday, 11'th Apr 2023
Santander will increase its stake in its Mexican unit to 99.8% from 96.2% following a tender offer for all outstanding shares in the business, the Spanish bank said on Tuesday, as it moves ahead with
Sanofi annonce le retrait et la resoumission du formulaire de notification et de rapport préalable à la fusion prévu par la loi HSR, ainsi que la prolongation de son offre publique d’achat sur le
Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.
08:15pm, Monday, 10'th Apr 2023 GlobeNewswire Inc.
Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.
Santander US CEO on leadership: ‘Building trust is key'
04:00am, Sunday, 09'th Apr 2023
In times of economic uncertainty, effective communication is critical for leadership. This includes transparency, frequent communication, and most importantly, authenticity.
Lending standards may change in response to deposit fears, says Santander's Stephen Stanley
01:53pm, Tuesday, 04'th Apr 2023
CNBC's Steve Liesman,and Stephen Stanley, chief US economist at Santander, joins 'The Exchange' to discuss dislocations in the market, the Fed's plan to drain excess liquidity, and the impact of bank
Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia
05:00am, Tuesday, 04'th Apr 2023 GlobeNewswire Inc.
Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia
